Provided by Tiger Trade Technology Pte. Ltd.

Arvinas Holding Company LLC

9.37
+0.34003.77%
Post-market: 9.370.00000.00%19:30 EDT
Volume:951.75K
Turnover:8.84M
Market Cap:612.34M
PE:70.06
High:9.39
Open:9.02
Low:9.00
Close:9.03
52wk High:14.51
52wk Low:6.97
Shares:65.39M
Float Shares:56.67M
Volume Ratio:1.77
T/O Rate:1.68%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.1337
EPS(LYR):-1.1400
ROE:1.59%
ROA:-1.01%
PB:1.09
PE(LYR):-8.21

Loading ...

Arvinas Announces FDA Approval of Veppanu (Vepdegestrant) for the Treatment of Esr1m, Er+/Her2- Advanced Breast Cancer

THOMSON REUTERS
·
May 02

Arvinas Inc - Co, Pfizer to Select Third-Party Partner for Veppanu Commercialization

THOMSON REUTERS
·
May 02

Arvinas Inc - FDA Approval Granted Before June 5, 2026 Pdufa Date

THOMSON REUTERS
·
May 02

US FDA approves Pfizer, Arvinas' breast cancer drug

Reuters
·
May 02

US FDA - Approves Guardant360 Cdx as Companion Diagnostic for Vepdegestrant

THOMSON REUTERS
·
May 02

Arvinas trading halted, news pending

TIPRANKS
·
May 01

NASDAQ TRADE HALT HALT NEWS PENDING AT 11:22 AM

Reuters
·
May 01

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Apr 30

Arvinas announces annual shareholder meeting via virtual webcast

Reuters
·
Apr 29

Tango Therapeutics names Matthew Gall CFO, replacing Daniella Beckman

Reuters
·
Apr 15

Arvinas Is Maintained at Buy by BTIG

Dow Jones
·
Mar 19

Analysts Have Conflicting Sentiments on These Healthcare Companies: ProKidney (PROK), HeartFlow, Inc. (HTFL) and Arvinas Holding Company (ARVN)

TIPRANKS
·
Mar 19

Wells Fargo Reaffirms Their Buy Rating on Arvinas Holding Company (ARVN)

TIPRANKS
·
Mar 19

Arvinas price target raised to $21 from $18 at Citi

TIPRANKS
·
Mar 19

Analysts Offer Insights on Healthcare Companies: Arvinas Holding Company (ARVN), HOYA (OtherHOCPF) and TransMedics Group (TMDX)

TIPRANKS
·
Mar 19

BUZZ-U.S. STOCKS ON THE MOVE-Vertex Pharma, U.S. Energy Corp, SoFi Technologies

Reuters
·
Mar 19

BUZZ-U.S. STOCKS ON THE MOVE-Tencent, Air Products, Protagonist

Reuters
·
Mar 18

BUZZ-Arvinas up after early-stage trial shows drug lowers key Parkinson's marker

Reuters
·
Mar 18

Arvinas Phase 1 trial shows ARV-102 achieves at least 50% LRRK2 reduction in Parkinson’s CSF by day 14

Reuters
·
Mar 18

Arvinas Announces Positive Phase 1 Data for Arv-102 Showing Greater Than 50% Lrrk2 Degradation in the Csf of Patients With Parkinson’s Disease Treated for 28 Days

THOMSON REUTERS
·
Mar 18